Prostamides (prostaglandin‐ethanolamides) and their pharmacology
- 1 February 2008
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 153 (3), 410-419
- https://doi.org/10.1038/sj.bjp.0707434
Abstract
The prostamides are part of a large and continually expanding series of pharmacologically unique neutral lipids. They are COX-2 derived oxidation products of the endocannabinoid/endovanniloid anandamide. Prostamide pharmacology is unique and, as in the case of the endocannabinoids anandamide and 2-arachidonylglycerol, bears little resemblance to that of the corresponding free acids. By virtue of its close relationship to the anti-glaucoma drug bimatoprost, prostamide F(2alpha) has received the greatest research attention. Prostamide F(2alpha) and bimatoprost effects appear independent of prostanoid FP receptor activation, according to a litany of agonist studies. Studies involving freshly isolated and separate feline iridial smooth muscle cells revealed that bimatoprost and FP receptor agonists stimulated different cells, without exception. This suggests the existence of receptors that preferentially recognize prostamide F(2alpha). The recent discovery of prostamide antagonists has provided further support for prostamide receptors as discrete entities. The prototypical prostamide antagonists, AGN 204396 and 7, blocked the effects of prostamide F(2alpha) and bimatoprost but not those of PGF(2alpha) and FP receptor agonists in the feline iris. Second generation more potent prostamide antagonists, such as AGN 211334, should allow the role of prostamides in health and disease to be elucidated. From the therapeutics standpoint, the prostamide F(2alpha) analogue bimatoprost is the most efficacious ocular hypotensive agent currently available for the treatment of glaucoma.Keywords
This publication has 69 references indexed in Scilit:
- Bimatoprost, Prostamide Activity, and Conventional DrainagePublished by Association for Research in Vision and Ophthalmology (ARVO) ,2007
- Fixed-combination and emerging glaucoma therapiesEmerging Drugs, 2007
- Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline irisBritish Journal of Pharmacology, 2007
- Upregulation of orphan nuclear receptor Nur77 following PGF2α, Bimatoprost, and Butaprost treatments. Essential role of a protein kinase C pathway involved in EP2 receptor activated Nur77 gene transcriptionBritish Journal of Pharmacology, 2004
- Comparison of Prostaglandin F2α, Bimatoprost (Prostamide), and Butaprost (EP2 Agonist) on Cyr61 and Connective Tissue Growth Factor Gene ExpressionPublished by Elsevier BV ,2003
- Pharmacological Characterization of a Novel Antiglaucoma Agent, Bimatoprost (AGN 192024)Journal of Pharmacology and Experimental Therapeutics, 2003
- Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamicsAmerican Journal of Ophthalmology, 2001
- Replacement of the carboxylic acid group of prostaglandin F2α with a hydroxyl or methoxy substituent provides biologically unique compoundsBritish Journal of Pharmacology, 2000
- Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptorBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonistBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995